The primary aim of this study is assessment of efficacy and safety data for trastuzumab, when used alone or in combination with standard chemotherapy, for the treatment of HER2-positive early stage breast cancer.
The combination of everolimus plus exemestane reduced bone turnover markers and halved rate of further bone metastases compared with exemestane alone in postmenopausal women with advanced breast cancer during the first 12 weeks of therapy.
In women with advanced breast cancer who had minimal previous exposure to adjuvant aromatase inhibitors (AI), the combination of fulvestrant and anastrozole “added no value” to anastrozole alone, results of a study in the Journal of Clinical Oncology published online February 27 concluded.
Approximately 25% to 30% of breast cancers are the result of the overexpression of the HER2 gene.
The combination of sunitinib plus docetaxel improved the objective response rate (ORR) but did not prolong progression-free survival (PFS) or overall survival (OS) vs. docetaxel alone for the first-line treatment of HER2/neu-negative advanced breast cancer, a Phase 3 randomized study concluded in the Journal of Clinical Oncology online February 13.
Adding everolimus to exemestane significantly improved progression-free survival (PFS) in women with hormone-receptor-positive advanced breast cancer previously treated with nonsteroidal aromatase inhibitors.
Patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer whose tumors also express hormone receptors may be less responsive to the addition of trastuzumab to chemotherapy, suggesting that hormone-receptor expression has a predictive role in determining response to therapy.
